Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717506 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
A Phase 3 study, sponsored by Balmoral Medical company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,236
- Enrollment target
NCT03717506 is a Phase 3 study that has completed, run by Balmoral Medical company. The registered enrollment target is 1,236 participants.
The verdict
NCT03717506, a Phase 3 study, has completed, sponsored by Balmoral Medical company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,236 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of acne vulgaris.
Interventions
- DRUG GDC 268 Lotion
- DRUG Clindamycin Phosphate Lotion 1%
- DRUG GDC Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,236 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717506
The ClinicalTrials.gov registry entry for NCT03717506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Balmoral Medical company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GDC 268 Lotion is the first listed.
NCT03717506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717506 about?
NCT03717506 is a clinical study titled "Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris". The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of acne vulgaris.
What is the current status of trial NCT03717506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,236 participants. The study started on 2018-10-10. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT03717506?
The interventions under investigation include: GDC 268 Lotion (DRUG), Clindamycin Phosphate Lotion 1% (DRUG), GDC Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT03717506?
This trial is sponsored by Balmoral Medical company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.